The FDA has approved label changes for six hormone replacement therapy (HRT) products for the treatment of menopause, removing boxed warnings about cardiovascular disease, breast cancer, and possible dementia[3][4]. These changes were approved on Thursday following a comprehensive review of the scientific literature, initiated in November 2025[3]. The products fall into four categories of HRT for menopausal women and are approved for the treatment of moderate to severe hot flashes, vaginal dryness, discomfort and prevention of bone loss[3]. Randomized trials show that women starting HRT within 10 years of the onset of menopause (usually before age 60) have reduced overall mortality and bone fractures[3][4]. These therapies can also reduce the risk of cardiovascular disease by up to 50%, Alzheimer's disease by 35%, and bone fractures by 50-60%[4]. In 2020, there were approximately 41 million women aged 45–64 in the US, but only about 2 million women aged 46–65 were prescribed HRT[3]. At the same time, the FDA approved a generic version of Premarin (conjugated estrogens), the first in more than 30 years, to improve availability and affordability[4]. The decision on the initiation and duration of HRT should be made by the doctor and the patient based on the benefits and risks[3][4].